Immunotherapies targeting peptides presented by allogeneic MHC molecules offer the prospect of circumventing tolerance to key tumor-associated self-antigens. However, the degree of antigen specificity mediated by alloreactive T cells, and their ability to discriminate normal tissues from transformed cells presenting elevated antigen levels, is poorly understood. We examined allorecognition of an HLA-A2-restricted Hodgkin's lymphoma-associated antigen and were able to isolate functionally antigenspecific allo-HLA-A2-restricted T cells from multiple donors. Binding and structural studies, focused on a prototypic allo-HLA-A2-restricted T-cell receptor (TCR) termed NB20 derived from an HLA-A3 homozygote, suggested highly peptide-specific allorecognition that was energetically focused on antigen, involving direct recognition of a distinct allopeptide presented within a conserved MHC recognition surface. Although NB20/HLA-A2 affinity was unremarkable, TCR/MHC complexes were very short-lived, consistent with suboptimal TCR triggering and tolerance to low antigen levels. These data provide strong molecular evidence that within the functionally heterogeneous alloreactive repertoire, there is the potential for highly antigen-specific "allo-MHC-restricted" recognition and suggest a kinetic mechanism whereby allo-MHC-restricted T cells may discriminate normal from transformed tissue, thereby outlining a suitable basis for broad-based therapeutic targeting of tolerizing tumor antigens.
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alloreactivity | cancer | tumor-associated antigen | immunotherapy M anipulation of T-cell allorecognition offers the prospect of powerful new therapies for hematological and solid tumors (1) . Importantly, although a minority of tumor-associated antigens (TAAs) are truly tumor-specific (2), many others, including universal TAAs, are expressed to some extent on untransformed tissues and in the thymus at levels sufficient to mediate effective antigen-specific T-cell tolerance (3, 4) . The result is a mature repertoire of self-MHC-restricted T cells devoid of potent effector capacity targeting specific TAAs. Such effects, thought to apply to several universal TAAs, such as the tumor suppressor p53 (5), the p53 regulator protein MDM2 (3, 6) , Cyclin D1 (7), and Wilms' tumor antigen WT1 (8) , contribute to poor autologous tumor immunity and represent a major hurdle in cancer immunotherapy.
T-cell allorecognition offers one route for circumventing selftolerance. After MHC-matched transplantation, allorecognition of novel minor histocompatibility peptide antigens (mHags) (1) arising from polymorphic changes in a peptide sequence (9, 10), or presentation of male antigens in female-to-male transplants, contributes to the graft vs. leukemia (GvL) effect promoting tumor eradication. However, GvL correlates with graft vs. host disease (1), a major cause of posttransplant morbidity. Hence, therapeutic strategies targeting mHags require careful selection of those expressed on tumors that preferentially induce GvL (1). An alternative therapeutic approach uses T-cell recognition of foreign MHC molecules (4). By carefully selecting "allo-MHCrestricted" T cells from HLA-mismatched donors, it is possible to obtain high-avidity recognition of TAAs that normally elicit poor-avidity autologous T-cell responses as a result of thymic tolerance (3, 8) . A prerequisite for such strategies is high antigen specificity. However, T-cell allorecognition of non-self-MHC molecules is thought to involve a wide span of functional properties with respect to peptide specificity. Although some studies have shown homology between T-cell receptor (TCR)/non-self-MHC and TCR/self-MHC recognition events (11), many have concluded allorecognition involves relatively low specificity for MHC-bound antigen (11) (12) (13) , with recent studies highlighting "polyspecificity" in the allogeneic repertoire (14) and highlighting both peptide-dependent and peptide-independent mechanisms (15, 16) . Second, allo-MHC-restricted T cells can discriminate between transformed cells expressing elevated TAA levels and untransformed cells (3, 6, 17, 18) . This property is likely to have a positive effect on clinical outcome when targeting tolerizing TAAs, and it remains poorly understood.
Here, we present a molecular analysis of allo-MHC-restricted TCR recognition of a predefined human TAA, latent membrane protein 2 (LMP2), expressed in Hodgkin's lymphoma, some Tcell/natural killer lymphomas, PTLD, and nasopharyngeal carcinoma (19) . We outline a mode of alloreactivity critically dependent on presentation of a distinct peptide by the allogeneic MHC molecule and suggest a kinetic mechanism by which allo-MHC-restricted T cells may specifically target cells expressing higher alloantigen levels.
Results
Functional Characterization of MHC-Mismatched T-Cell Clones. LMP2, encoded by EBV, was chosen as a model TAA for allo-MHCrestricted targeting. A viral (rather than tolerizing) TAA had the advantage of ultimately allowing comparison of allo-MHC-restricted and self-restricted responses to the same TAA. LMP2, expressed in most EBV-associated tumors, contains many recognized cytotoxic T-lymphocyte (CTL) epitopes. To generate allo-MHC-restricted and self-MHC-restricted responses to the LMP2 epitope CLGGLLTMV (CLG), peripheral blood mononuclear cells (PBMCs) from HLA-A2
− and HLA-A2 + donors were cultured with CLG peptide. Comparisons of CTL responses to HLA-A2 + targets with or without CLG peptide showed selfrestricted clones were relatively homogeneous, exhibiting substantial responses to CLG-pulsed targets and low background HLA-A2 reactivity (Fig. S1A, Right) . In contrast, alloreactive clones from HLA-A2 − donors were functionally heterogeneous, with some exhibiting similar cytolysis irrespective of CLG antigen and others apparently as CLG-dependent as self-restricted clones (Fig. S1A, Left) . There was considerable variability in HLA-A2 − donors, with some biased toward peptide-insensitive recognition and others toward peptide-dependent recognition (Fig. S1A) . The diverse allo-T-cell clones segregated into three groups (Fig. S1B) . Some (e.g., NM12), were alloreactive to HLA-A2 but insensitive to CLG peptide. For a second set (e.g., NW21), HLA-A2 alloreactivity was enhanced to a greater or lesser extent by CLG peptide. However, for a third group typified by NB20, recognition was entirely dependent on both CLG peptide (Fig. S1B, Upper) and HLA-A2 (Fig. S1C) , and could thus be classed as allo-MHCrestricted. The prototypic allo-HLA-A2-restricted NB20 clone was from an HLA-A3 homozygote, and bound HLA-A2-CLG tetramers (Fig. S1C) . Whereas NB20 lysed HLA-A2 + cells only when pulsed with CLG peptide (Fig. S1 B and C) , no lysis of HLA-A2
− targets was observed irrespective of CLG peptide (Fig.  S1C) . Analogous results were obtained in IFN-γ secretion assays. These results confirm NB20 was allorestricted to HLA-A2 and specific for the CLG alloantigen.
Finally, self-and allo-MHC-restricted clones showed different functional avidities. Self-restricted clones often had a half-maximal target cell lysis of ∼10 −10 M (Fig. S1D , Upper) and frequently killed HLA-A2
+ EBV + lymphoblastoid cell line (LCL) without exogenous CLG (20) . In contrast, allo-HLA-A2-restricted T-cell clones (e.g., NB20, NM06) had functional avidities of ∼10 −8 M (Fig. S1B ), more comparable with low-avidity selfrestricted clones (Fig. S1D, Lower) , and often failed to recognize EBV + LCL without exogenously added CLG. NB20 was tolerant to the low levels of CLG antigen on EBV + LCL but was selectively sensitized to lyse the same cells after pulsing with additional exogenous CLG (Fig. S1C) . Hence peptide-specific allo-MHC-restricted T cells reside within a functionally diverse alloreactive repertoire and, at least for the CLG peptide, often exhibit somewhat lower functional avidities than self-restricted T cells. To probe allo-HLA-A2-restricted CLG recognition, we produced soluble NB20 TCR and assessed NB20/HLA-A2 binding using surface plasmon resonance (SPR) (10, 21, 22) . NB20 injection elicited greater responses over HLA-A2-CLG flow cells than control surfaces, indicating specific binding (Fig. 1A) . Injection over HLA-A2-containing irrelevant peptide yielded responses matching those over blank surfaces or control HLA-B7 complexes, indicating HLA-A2 recognition was entirely dependent on the presence of the target alloantigen (Fig. 1A) . Equilibrium affinity measurements (Fig. 1B) showed NB20 bound to immobilized HLA-A2-CLG with a K d of 28.8 μM ± 5 (n = 17), and was similar in the reverse orientation (Table 1 and Fig. S2A ). Thus, the NB20/HLA-A2-CLG affinity is similar to self-restricted TCR/MHC interactions (23). ) and dissociation (k off 10
-10
) rate constants than other interactions of similar affinity (typically,
, k off ∼1 s −1 ) because of structural rearrangements [e.g., of complementarity determining region (CDR) loops] on complex formation (24) . To determine the kinetics of NB20/HLA-A2-CLG allorecognition, NB20 was injected at high flow rates over low levels of immobilized HLA-A2-CLG to eliminate mass transport effects. NB20/HLA-A2-CLG binding reached equilibrium rapidly (<0.5 s), making direct k on estimation impossible, as noted previously (22) . NB20/HLA-A2-CLG dissociation was also extremely fast, with a k off of 8.8 s −1 (Fig. 1C) , irrespective of orientation (Table 1 and fold faster than other TCR/MHC complexes measured similarly (25) and equates to a complex half-life (t 1/2 ) of ∼80 ms (Fig.  S2C ). Using the affinity (K d = 28 μM) and k off of 8.8 s
, the association rate constant was calculated to be 3.1 × 10 5 M
, which is much faster (∼10-to 1,000-fold) than for most self-restricted TCR/MHC interactions (25) . Also, whereas previous analyses have shown TCR/MHC binding is generally enthalpically driven and entropically costly (25) , the NB20/HLA-A2-CLG K d was similar at 37°C (Fig. S2A) , consistent with fast association kinetics (Table 1) .
Multiple Alloantigen Residues Contribute to Specificity of the NB20 TCR. To assess how CLG peptide-specific NB20 recognition was, we used SPR to test NB20 binding to HLA-A2 presenting CLG peptides with single alanine substitutions at each nonanchor position (C1A, G3A, G4A, L5A, L6A, T7A, and M8A), in comparison to the index CLGGLLTMV epitope. Five changes (G3A, L5A, L6A, T7A, and M8A) substantially decreased binding, indicating a high degree of specificity to the alloantigen (Fig. 1D , Table 2 , and Fig. S3A ). L6A and T7A caused four-to six-fold affinity reductions, and L5A and M8A eliminated binding. In contrast, C1A and G4A had little or no effect on K d . The most striking reductions involved changes in larger residues, clustering at central and C-terminal regions of CLG (L5, L6, T7, and M8), whereas smaller side chains (C1, G3, and G4) had minor effects.
Energetically Significant Contacts at the TCR/Allo-MHC Interface. To assess the relative energetic contribution of peptide and MHC to allorecognition and define the NB20 binding mode, its affinity for a panel of HLA-A2 mutants was tested by SPR ( Fig. 1E and  Fig. S3B ). The panel comprised single alanine substitutions at solvent-exposed α1-α2 helix residues, involving known contact sites for HLA-A2-restricted TCRs (26) . Although many mutants had no effect, five substantially altered the K d (Fig. 1 E and F and Table S1 ). On the α1 helix, those near N-terminal/central CLG regions had small effects but those near the C terminus at Q72 and V76 moderately decreased affinity (∼2-fold). This suggests a TCR variable (V) β footprint similar to self-restricted TCRs (26) . On the α2 helix, Q155A increased affinity ∼10-fold, largely attributable to a decreased k off (Fig. S3C) . In contrast, mutation of Y159, which often contacts antigenic peptide, eliminated binding. These data suggest a TCRα footprint similar to selfrestricted TCRs, over the central α1 helix region, and indicate Q155 aids complex dissociation. Finally, K146A also eliminated binding, suggesting a crucial role. Because K146 is near energetically important C-terminal allopeptide residues, is distal to the putative TCR Vα position, and does not contact self-restricted HLA-A2-restricted TCRs, we hypothesized a role in stabilizing CLG peptide.
Structure of the HLA-A2-CLG Alloligand to 1.9 Å. To understand roles of specific residues in allorecognition, the HLA-A2-CLG crystal structure was determined to 1.9 Å (Fig. 2 A-C and Table  S2 ), enabling the NB20 energetic footprint to be mapped on it. Consistent with mutagenesis, the short C1 peptide side chain is in the least prominent section of CLG and is probably ignored by NB20 (Fig. 2B) . In contrast, L5, L6, and M8 (Fig. 2 D-F) , mutation of which substantially reduced affinity, were solvent-exposed and in prominent sections of CLG, suggesting direct contact to NB20. Orientation of L6 and M8 toward the α1 helix and their proximity to solvent-exposed α1 residues Q72 and V76 (Fig. 2E) , also implicated as important by mutagenesis, highlight these residues as a probable TCRβ footprint. In contrast, L5, orientated toward the α2 helix, is a more likely target for TCRα recognition. T7 was solvent-inaccessible, pointing toward the groove floor (Fig. 2 C and E) , mediating hydrogen bonding contacts to R97. This suggested a role for T7 in stabilizing CLG conformation in a region critical for NB20 recognition, supported by the greater than fourfold decrease in affinity of the T7A mutant.
The HLA-A2-CLG structure also explained effects of α2 helix mutation Q155A, which increased affinity by ∼10-fold, and α2 helix mutations Y159A and K146A, which eliminated binding. Q155 is positioned centrally on the α2 helix, adjacent to L5 (Fig.  2D) . TCR contacts to L5 are likely to be energetically highly significant because L5A eliminates binding. However, Q155 packs closely (3.4-4.5 Å) against L5, potentially interfering with TCR binding. Also, Q155 points directly up toward the TCR, whereas L5 protrudes toward the α2 helix, thereby presenting a less prominent target for the TCR. This suggests Q155 acts as a "gatekeeper" for NB20 allorecognition, as for self-restricted TCR/MHC binding (27) , and its reorientation may be required during NB20/HLA-A2-CLG interaction to facilitate optimal allopeptide contacts (28) . The major effect of Q155A is to decrease the k off (∼8-fold), suggesting the key role of Q155 is in effecting complex dissociation.
Although a possible NB20 contact, Y159 presents a low profile to NB20, protruding laterally toward the groove (Fig. 2D) . However, by interacting with CLG at P1-P3, it stabilizes its conformation around the flexible G3-G4 region. The drastic effect of Y159A may therefore reflect perturbation of CLG structure in the absence of these contacts. Similarly, K146 also points toward CLG (Fig. 2F) , hydrogen-bonding with M8. K146 therefore stabilizes CLG conformation in an energetically critical region for TCR binding, and may also directly contact NB20; in such case, its CLG-specific conformation would be a component of antigen-specific recognition. Hence, the drastic effects of Q155A, Y159A, and K146A highlight similarities with self-restricted TCR/MHC interactions and the highly peptide-specific nature of NB20 allorecognition.
Structure of the NB20 TCR to 2.2 Å. To understand the structural basis of NB20 allorecognition, we solved the NB20 structure to 2.2 Å (Fig. 3 A and B and Table S2 ). Constant and V-domains were structurally similar to other TCRs (rmsd: 1.2-2.2 Å), with analogous domain orientations and interdomain packing. CDR loops protruded equivalently from the V-domain, suggesting a relatively flat binding surface. CDR loop B-factors were higher than V-domain framework regions, especially for CDR3 (Fig.  S4) , suggesting conformational flexibility, as for self-restricted TCRs (25) . CDR-1 and CDR-2 loop conformations were markedly similar to TCR structures in complex with HLA-A2 (Fig. 3C) , especially for Vβ13 chain CDR-1 and CDR-2 loops also used by the A6/B7 TCRs (29, 30) . NB20 may therefore use a TCRβ footprint similar to self-restricted TCRs, supported by our mutagenesis data. Consistent with an antigen-specific recognition mode, CDR3 loops were the most distinct features compared with other TCR structures (Fig. 3C) .
Comparison of Self-Recognition (HLA-A3) and Allorecognition (HLA-A2) Surfaces. Our analyses allowed us to assess the role of HLA-A α1-α2 polymorphisms in allorecognition. NB20, allorestricted to HLA-A2, underwent thymic selection in an individual homozygous for HLA-A3, the allele likely responsible for its positive selection. Comparison of HLA-A2 and HLA-A3 highlighted polymorphisms that may contribute to allorecognition by directly contacting NB20 (Fig. 4) . Although five polymorphic residues on the α1-α2 helices are solvent-exposed (62, 66, 142, 145, and 161), these are unlikely to contact NB20 directly because they are either distal to energetically significant areas or orientated away from the TCR (Fig. 4A and SI Text) . In contrast, analysis of HLA-A2-CLG highlighted a clear role for polymorphisms in CLG peptide presentation (Fig. 4 B and C) . Several CLG residues interact with polymorphic residues of the HLA-A2 altered in HLA-A3, and these interactions are unlikely to be conserved in HLA-A3. In summary, multiple polymorphic residues play key roles in stabilizing CLG binding to HLA-A2. This conclusion is consistent with the distinct peptide binding motif of HLA-A3 and HLA-A2 (31) , and the inability of HLA-A3 to present the CLG peptide.
Discussion
Circumvention of tolerance to TAAs is a key requirement for cancer immunotherapy strategies. Allo-MHC-restricted targeting can be applied to any TAA, in principle, and is one promising route to achieving this, particularly in light of advances in TCR gene transfer. Indeed, an allo-MHC-restricted TCR specific for WT1 is undergoing phase 1/2 clinical trials for treatment of acute myeloid leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome using a gene transfer approach. Successful clinical application of such strategies requires allo-TCR specificities that precisely target defined TAAs. However, although studies on allo-TCR/MHC recognition events have indicated homology with self-restricted interactions, they have also emphasized low peptide specificity, limited TCR-mediated peptide contacts, unusual TCR/MHC footprints, and fortuitous cross-reactivity with nonhomologous peptides (11) (12) (13) . Allo-TCRs with such properties are unlikely to form the basis of antigen-specific immunotherapeutic strategies. Only more recently have studies highlighted the potential for peptide specificity in allorecognition, and the underlying molecular mechanisms have hitherto remained unclear.
Our results provide firm molecular evidence that a subset of alloreactive interactions that include allo-MHC-restricted TCR/ MHC recognition events is very analogous to self-restricted TCR/ MHC interactions and involves high specificity for MHC-bound peptide. NB20 bound its alloligand HLA-A2-CLG with a K d in the range of self-restricted interactions and did not bind irrelevant HLA-A2 peptides or other class I MHC molecules, consistent with the properties of the NB20 T-cell clone and analogous to self-restricted TCRs. Use of CLG variants underlined the importance of multiple peptide residues in NB20 recognition, most of which (L5, L6, and M8) have large exposed side chains prominently positioned in the alloligand structure, indicating direct interaction. In contrast, CLG recognition was unaffected by P1 substitution in the least prominent section of CLG. This specificity pattern resembles that of self-restricted TCRs (26) and is in keeping with recent cellular studies in mice suggesting an important role for endogenous peptide in alloreactive responses (32) . Compared with peptide, HLA-A2 mutations generally had minor effects on affinity, consistent with NB20 focusing energetically on the allopeptide. Strikingly, the three exceptions all involved amino acids (Q155, Y159, and K146) contacting allopeptide, and for Q155 and K146, these were with energetically critical peptide residues, further underlining NB20 peptide specificity. These points suggest allo-MHC-restricted TCR/ MHC interactions can achieve the high peptide specificity required of antigen-specific immunotherapy applications.
Our energetic and structural evidence also suggests NB20 recognition may closely resemble self-restricted interactions. The α1 helix mutations affecting NB20 binding were close to energetically significant central/C-terminal peptide residues. In light of the accepted constraints on TCR/MHC orientation whereby the Vβ and Vα domains are universally oriented over the α1 and α2 domains, respectively (25) , these data suggest a TCRβ footprint analogous to self-restricted TCRs (26) . Accordingly, the NB20 TCR Vβ chain is shared by A6 and B7 TCRs that form Vβ-mediated contacts in this same region, and the Vβ CDR1 and CDR-2 loop conformations of NB20 are similar to the HLA-A2-bound A6 and B7 TCRs (29, 30) . Similarly, mutational analysis suggested a central TCRα footprint, consistent with a diagonal TCR binding mode, as for many self-restricted TCRs (26) . The high CDR loop B-factors suggest flexibility in the TCR binding site, as for self-restricted TCRs (26) . Finally, the indications that Q155 may be required to reorientate during NB20 binding suggest that as for self-restricted TCRs, it may act as a gatekeeper for TCR engagement (27, 28) .
Our study provides a molecular basis for allo-MHC-restricted TCR recognition events. The NB20 energetic footprint indicates allorecognition involves an MHC recognition surface highly conserved between allogeneic and self-MHC. In contrast, the HLA-A2-CLG structure highlighted buried polymorphisms altered in allo-MHC (HLA-A2) vs. self-MHC (HLA-A3) were key in facilitating presentation of the allopeptide. Although the possibility that buried polymorphisms may contribute to allorecognition, in part, by mediating conformational alterations in the apparently conserved α1/α2 helix residues cannot be completely excluded, the collective NB20 dataset strongly favors a molecular mechanism for allo-MHC restriction critically dependent on interaction with a distinct allopeptide in a conserved TCR/MHC recognition interface. Given this, how widespread is the potential for allo-MHC restriction in the self-restricted repertoire? Self-restricted TCR/ MHC structures indicate most MHC polymorphisms contacted by the TCR are conserved in many alleles, suggesting considerable allo-MHC restriction potential (4, 30) . Also, this may be favored by the requirement for self-restricted TCRs to recognize multiple peptides (33) , by TCR binding site flexibility (24, 26) , and because not all peptide side chains are TCR contacts (26) . Accordingly, we generated multiple allorestricted CTL clones with NB20-like properties from several individuals. Moreover, the allorestricted repertoire specific for individual antigens is highly diverse (34) , suggesting allo-MHC-restricted immunotherapeutic strategies have the potential to target a broad range of TAAs.
Although most properties of NB20/HLA-A2-CLG binding closely resemble self-restricted interaction, the NB20 binding kinetics are notably faster (25) , with a strikingly fast off-rate (8.8 s −1 , t 1/2 = 80 ms). Conceivably, such kinetics are nonphysiological and reflect the alloreactive nature of the interaction. Alternatively, similar kinetics may occur during self-restricted responses but may not be favored during in vivo maturation of the T-cell response, whereas the in vitro methods we used can support selection of clones with unstable interactions with ligand. Indeed, murine data suggest a selection bias for T-cell access to the memory compartment, with primary cells interacting more stably with cognate peptide-MHC strongly favored (35) . Notably, most self-restricted TCR/MHC binding data relate to memory T cells. In contrast, fast NB20 kinetics may reflect the limited chance of obtaining optimal kinetics for T-cell recognition by in vitro selection from a limited pool of peripheral T cells, rather than self-restricted T cells that undergo powerful in vivo selection from a vast naive T-cell repertoire. These ideas suggest TCR/MHC kinetics distinct from those of memory T cells may be common for allo-MHC-restricted TCR/MHC interactions, a possibility that future studies will help to resolve.
Our study also has implications for allorecognition at the cell surface. TCR/MHC affinity and stability correlate with the strength of agonistic T-cell signaling (25) . Also, although TCR/ MHC interaction is stabilized by coreceptor/MHC binding, the latter is extremely weak with rapid dissociation kinetics, suggesting the TCR dominates the kinetics of peptide-MHC engagement (36) . Notably, NB20 affinity is sufficient for independent cell surface binding (37) , and its kinetics are compatible with TCR triggering. Indeed, transduction of NB20 chains conferred antigen-specific CTL killing and cytokine production (38) . Generally, fast TCR/MHC dissociation may compromise antigen sensitivity because it will impede retention of interacting TCRs in close-contact zones, whereas more stable interactions are retained (36) . However, such effects may be overcome at higher antigen concentrations, particularly because the fast NB20 k on may facilitate rebinding and retention of the TCR/MHC pair in the close-contact zone, a suggestion supported by recent work emphasizing the importance of k on in determining the effective t 1/2 or "confinement time" of a TCR-pMHC interaction (39) . Consistent with this, NB20 ligand recognition was quite insensitive to antigen relative to many memory T cells of the same specificity. In the context of a tolerizing TAA, fast dissociation is one potential mechanism as to how allo-MHC-restricted T cells discriminate transformed cells presenting elevated TAA levels from normal tissues presenting low levels. Future studies may determine if such properties are a common feature of allo-MHC-restricted recognition or if other mechanisms may explain functional specificity of allo-MHC-restricted T cells for transformed cells. 
Experimental Procedures
Cellular Assays and Generation of T-Cell Clones. T-cell clones were generated Soluble TCR and MHC Class I Preparation. NB20 genes were isolated by RACE PCR using 3′ primers for TCRα and TCRβ C regions. For binding studies, TCR-leucine zipper fusion protein was produced in Escherichia coli (21) . For crystallization, TCR was produced containing an interchain disulfide bond (40) . Refolded TCR was purified by ion exchange and gel filtration. For binding studies, HLA-A2 heavy chain (with a biotinylation tag) was expressed in E. coli and refolded (41), with synthetic CLG peptide, CLG variants, or control peptides, as well as β 2 M. Refolding was followed by enzymatic biotinylation and gel filtration. Mutant HLA-A2 molecules were generated using the QuikChange Kit (Stratagene) and refolded as above. The conformation of mutant and CLG variant complexes was verified by CD, using a JASCO J-810 Spectropolarimeter, as described (10) . For crystallization trials, HLA-A2-CLG was refolded as described (41) . Protein was quantitated by OD at 280 nm using extinction coefficients of 66,150 M SPR. SPR studies used a BIAcore 3000 in HBS-EP, as described (24) . Biotinylated MHC complexes were immobilized by injection over streptavidin-coupled surfaces. NB20 TCR was purified by gel filtration before use to eliminate protein aggregates. Equilibrium affinity measurements involved injecting NB20 over immobilized MHC complexes at 5 μL/min. Kinetic measurements were carried out at high flow rates (50-100 μL/min) and low MHC immobilization levels (250-500 resonance units). Data analysis was performed using BIAevaluation 3.1 and Microcal Origin.
Protein Crystallization. Crystallization trials were performed at 23°C. HLA-A2-CLG (8 mg/mL) was crystallized in hanging drops in 22% (wt/vol) PEG 3350, 0.2 M ammonium iodide. NB20 (11 mg/mL) was crystallized in sitting drops in 21.5% (wt/vol) PEG 4K, 0.2 M ammonium acetate, 0.1 M citric acid (pH 4.0).
X-Ray Data Collection, Structure Determination, and Refinement. Data were collected from single crystals at the European Synchrotron Radiation Facility, processed with MOSFLM (42), and scaled using CCP4. HLA-A2-CLG and NB20 TCR structures were solved by molecular replacement in Crystallography & NMR System (CNS) (43) using an HLA-A2 complex and the JM22 TCR (PDB ID code 1OGA) as search models. Model manipulations in COOT (44) were interspersed with rounds of refinement using CNS. Data collection, processing, refinement, and model geometry statistics are listed in Table S2 . Coordinates and structure factors have been deposited in the Protein Data Bank [PDB ID codes 3REV (NB20 TCR) and 3REW (HLA-A2-CLG)].
